BRAF and melanoma: BRAF mutation predicts shorter OS in stage IV melanoma (10), which is consistent with clinical outcomes of tumor regression upon Vemurafenib administration in advanced melanoma patients; inhibition of a marker that is directly associated with poor prognosis results in prolonged survival.